Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

The LUMINA Study

Graciela S. Alarcon, MD, MPH  |  Issue: April 2011  |  April 13, 2011

The main contributions that the LUMINA cohort has made to advance our knowledge about lupus can be summarized as follows:

1) We have called attention to the seriousness of lupus among Hispanics (primarily of Native American background), which in many ways mirrors the disease observed in African Americans. Of note is the similar frequency of renal disease (62%), which contrasts with the frequency observed among Caucasians and Puerto Rican Hispanics (about 25% to 26%), damage accrual (more rapid accrual and of greater magnitude), disease activity (greater), and survival (diminished). Although it would be easy to ascribe these findings to the presence of ancestral Native American genes among these Hispanic patients, when socioeconomic variables are taken into consideration, some of the differences observed between the ethnic groups can be accounted for by socioeconomic factors.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

I hope, therefore, that by focusing attention on the seriousness of lupus among persons of Hispanic descent … we will meet a growing challenge in public health.

In the case of disease activity, ethnicity remains an explanatory variable when examining factors that contribute to disease activity early in the course of the disease but not when examining those that contribute to disease activity over time. In the case of renal disease occurrence, by contrast, ancestral genes and the combination of ancestral genes and socioeconomic factors contribute to the increased predisposition to renal disease observed among Texan Hispanics and African Americans, probably as a result of difficulties in accessing healthcare and lower response rates to currently available therapies. Other observations also support the importance of socioeconomic factors as important modulators of clinical events in lupus; for example, even though adverse pregnancy outcomes were observed more frequently among the Texan Hispanics and the African Americans than among the Caucasians and Puerto Rican Hispanics, it was education (low level) rather than ethnic group the variable that remained in multivariable explanatory models.1

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE
<strong>Figure 3:</strong> Confounding by indication
click for large version
Figure 3: Confounding by indication

2) We have demonstrated the importance of socioeconomic factors as contributors to survival in lupus. If we examine the most recent mortality data in lupus from the Centers for Disease Control and Prevention, one observes the disparate curves between African-American and white patients (see Figure 1); importantly, the mortality rates for African Americans seem to have increased over the last few years. Unfortunately, no data for Hispanics are noted in this publication. In univariate analyses, we have also shown that the survival curves are quite disparate (see Figure 2), with African Americans and Hispanics from Texas, exhibiting lower survival than the Caucasians and Puerto Rican Hispanics. However, in multivariable analyses (repeatedly conducted over the years), we have shown that it is poverty and not ethnicity that is an independent contributor to a diminished survival (see Table 1).2–5

Page: 1 2 3 4 5 6 | Single Page
Share: 

Filed under:ConditionsSystemic Lupus Erythematosus Tagged with:Diagnostic CriteriaPathogenesispatient careSystemic lupus erythematosusTreatment

Related Articles

    University of Alabama at Birmingham’s Division of Clinical Immunology & Rheumatology Recognized for Excellence

    June 13, 2016

    An interdisciplinary and collaborative environment is a critical factor for the advancement of basic science and clinical research in the academic environment, says William J. Koopman, MD, former director of the University of Alabama at Birmingham’s (UAB’s) Division of Clinical Immunology and Rheumatology. And in 1977, when he was being recruited by Division Director J….

    Rawpixel/shutterstock.com

    Racial Disparities Result in Unprecedented Differences in Outcomes for SLE Patients

    October 13, 2015

    The differences between Caucasian and minority patients with lupus are striking: In almost all aspects of the disease, black, Hispanic and many Asian lupus patients do poorly compared with their white counterparts. Although racial disparities in outcomes in the practice of medicine are widespread, the scope and degree of the differences in lupus is, with…

    Pitfalls of Potential Lupus Diagnosis

    June 13, 2016

    Spotting the signs of autoimmunity as early as possible is often viewed as a positive goal for rheumatologic research. The premise: Patients may begin treatment years before their disease is active and destroying joints and tissue. Although much progress has been made in identifying early stages of rheumatoid arthritis pathogenesis, the clues are not as…

    Summer 2022’s Awards, Appointments & Announcements in Rheumatology

    June 14, 2022

    Medal for Excellence Awarded to Graciela Alarcón, MD Graciela (Chela) S. Alarcón, MD, MPH, is the emeritus Jane Knight Lowe Chair of Medicine in Rheumatology at the University of Alabama at Birmingham (UAB), and a professor of medicine (emeritus) at Universidad Peruana Cayetano Heredia (UPCH), Lima, Perú, her alma mater. Last fall, she received the…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences